Introduction {#sec1-1}
============

Cytochrome P~450~ (CYP~450~) enzymes belong to a superfamily of hemoproteins that play an important role in the metabolism of endogenous as well as exogenous compounds, such as drugs of clinical importance, carcinogens, steroids, and cholesterol (Liu, 2010; Sarkar et al., 2003). These enzymes are also charged with metabolizing thousands of bioactive compounds of plants with very diverse chemical structures (Laursen et al., 2011). These enzymes are the main mechanism for increased, diminished, or null bioavailability of herbal-based drugs and compounds when said enzymes and drugs are simultaneously administered (Pekthong et al., 2009; Wang et al., 2009). They are termed P450 because an absorbance peak is produced at 450 nm when treated with a reducer agent and linked with carbon monoxide (Pan et al., 2011). In rats, the CYP450 enzymes commonly involved in the metabolism of xenobiotics include CYP1a2, CYP2c11, CYP2e1, and CYP3a1/2 (Li et al., 2008), while in humans, the enzymes involved are CYP1A2, CYP2C9, CYP2D6, and CYP3A4 (Ponnusankar et al., 2011; Zhou et al., 2011). The overexpression of CYP3A4 has been reported to contribute to the development of leukemia, prostate cancer, and breast cancer (Keshava et al., 2004). A decrease in CYP3A4 overexpression appears to reduce the risk of cancer in children (Swinney et al., 2006). In rats, the CYP3A subfamily is the second in importance, followed by Cytochrome 2C11, with an abundance of 39%; however, the CYP3A subfamily is responsible for metabolizing 50--60% of all currently employed drugs: it is thus the most important and abundant enzyme in the human organism (Dally et al., 2003; Zhou et al., 2007). CYP3A is expressed mostly in the liver and the gastrointestinal tract (Chen et al., 2009). People tend to combine different plant preparations with modern prescription drugs, in that they consider it safe to consume herbal derivatives; such combinations can produce plant-drug interactions (Pekthong et al., 2009). *Ruta chalepensis* (*R. chalepensis*) is native to southern Europe and the Eastern Mediterranean region, where it is known as *Ruda*; this plant is cultivated in the greater part of the American continent. By virtue of its analgesic and antipyretic effects, it has been used in the treatment of neuralgia, rheumatism, and menstrual disorders (al-Said et al., 1990), as an abortive and antirheumatic, for intestinal and hepatic diseases, as an antiepileptic and antipyretic, it is also useful in perfumery, and it has insecticidal activity (Pino et al., 2014; Di Stasi et al., 1994). Phytochemical screening of *R. chalepensis* has shown the presence of campherol, rutin, quercetin, bergapten, chalepsin, psoralen, skimmianine, kokusaginine, graveoline, furoquinoline, γ-fagarine, dictamnine, arborinine, and chalepensin (Schmelzer and Gurib-Fakim, 2013), as well as coumarins, which are employed in the treatment of the symptoms of multiple sclerosis (Orlita et al., 2008). Flavonoids, glycosides, and tannins are considered potent pro-inflammatory molecule inhibitors. In this study, we employed the aqueous-type *R. chalepensis* extract used by popular medicine in the form of an infusion and/or decoction from the plant (Khadhri et al., 2017).

Materials and Methods {#sec1-2}
=====================

Preparation of the aqueous extract of R. chalepensis {#sec2-1}
----------------------------------------------------

Five kg of fresh *R. chalepensis* plant specimens were acquired in the North of Mexico (25.53607 N, 103.52117 W). The plant material was dried for 10 days at room temperature. The aerial parts were ground to a fine powder. One hundred g of fresh powder was weighed, and 1,000 mL of distilled water was added; the mixture was heated to 100º C, shaken for 1 h, and then filtered with Whatman Nº 1 filter paper using a vacuum pump. The filtrate was taken to dryness in a furnace set at 40ºC to obtain the dry extract, which was stored at 5ºC in the dark until it was used. A voucher specimen of *Ruta chalepensis*, numbered 60663, was deposited in the Herbarium of the Benemérita Universidad Autónoma de Puebla (BUAP), Mexico.

In vivo study with Wistar rats {#sec2-2}
------------------------------

We placed 25 male 11-week old Wistar rats in five cages, five animals per cage. The weights of the rats were between 250 and 300 g. For seven days prior to the treatment, the rats were maintained under standard laboratory conditions (temperature 24ºC, 12-h light/dark cycles, 45% relative humidity) with ad libitum access to pellets (Teklad^®^ 18% protein) and water. None of the animals was replaced during the study. The experimental protocol was approved by the Bioethics Committee of the Universidad Autónoma de Coahuila, Facultad de Medicina, in Mexico, with approval number 0100-10. The rats were treated via intraperitoneal (i.p.) injection with 100 and 30 mg/kg/day of *R. chalepensis* extract, respectively, for groups 1 and 2. Another group was administered 100 mg/kg/day of Dexamethasone (DEX) combined with 100 mg/kg/day of *R. chalepensis* extract. As a positive control, one group was administered 100 mg/kg/day of DEX. We employed saline solution (0.9%) as vehicle with all of the groups at a dose of 6.67 mL/kg/day, with the exception of the positive control group, which was administered corn oil (6.67 mL/kg/day) for 3 consecutive days. After the last administration session, all rats were fasted for 24 h, were then anesthetized with ether, sacrificed, and their livers were extracted; the liver tissues were placed in RNALater^®^ until they were processed.

Extraction of messenger RNA (mRNA) {#sec2-3}
----------------------------------

Livers were cut into 3-mm-thick slices, which were submerged in RNALater^®^ (Qiagen^®^, USA); these samples were stored at 4ºC for 24 h for RNase inactivation, and were later frozen at --20ºC until they were processed. The mRNA was isolated utilizing the RNeasy Protect Mini Kit (Qiagen^®^, USA), following the manufacturer's instructions.

Real-time quantitative PCR, Reverse Transcription, and qPCR (qRT-PCR) {#sec2-4}
---------------------------------------------------------------------

We employed the primers 5´-TTCACCGTGATCCACAGCA-3´ and 3´-TGCTGCCTTGTTCTCCTT-5´ of CYP3a1; these were confirmed in GenBank with access number L24207; as control, we utilized GAPDH (Taqman^®^ Rn01775763_g1) ((Morioka et al., 2006).

For amplification, we used TaqMan^®^ catheters with 50 denaturation cycles of 15 sec at 92ºC. Hybridization was carried out for 90 min at 60ºC. The qRT-PCR reaction was developed using Applied Biosystem 7300^®^ equipment and the Techne^®^ Thermocycler.

Toxicity test in microplates {#sec2-5}
----------------------------

In order to calculate the median Lethal Dose (LD~50~), we employed the *Artemia salina* larval bioassay (San Francisco Bay Brand Brine Shrimp Eggs^®^); we placed 20g of cysts in 500 mL of Instant Ocean^®^ Sea Salt, and the pH value was adjusted to 7.8 for cyst incubation at a temperature of 22--25°C for 48 h under a white light lamp. After this, we prepared dilutions of 50, 125, 250, 750, and 1,000 ppm. We inserted 10 nauplii per well, and 24 h later, we counted the dead and live nauplii. In the toxicity bioassay, larvae were considered dead when no movement was observed after observation for a number of seconds (Carballo et al., 2002). The calculation of LD~50~ was obtained using Minitab software (v. 15.0 for Windows; State College, PA, USA). The toxicity criteria employed are in agreement with those utilized by Bastos et al. (2009) and Déciga-Campos et al. (2007), where LD~50~ values \>1,000 µg/mL are non-toxic, values ≥500 and ≤1,000 µg/mL have weak toxicity, and values \<500 µg/mL are toxic.

Statistical analysis {#sec2-6}
--------------------

Difference between groups was obtained using the non-parametric Mann--Whitney *U* analysis. The LD~50~ was determined by linear regression analysis using the SPSS Science statistical software (v. 15.0 for Windows; SPPS, Inc., Chicago, IL, USA), as well as GraphPad Prism (v. 5.0 for Windows; San Diego, Ca, USA), and Minitab (v. 15.0 for Windows; State College, PA, USA). The significance level was established at *p* \<0.05.

Results {#sec1-3}
=======

Effect of the treatment with aqueous extract of Ruta chalepensis on Wistar rats {#sec2-7}
-------------------------------------------------------------------------------

Body Weight (BW) was not affected by the treatment (data not shown). Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} present the mRNA levels obtained from the treatment groups in comparison with the control group, which was treated with saline solution only. Treatment for 3 consecutive days with DEX (100 mg/kg/day) caused an inducer effect 9.94-fold that of cytochrome; in the treatment groups, the effect was inversely proportional to the concentration of the extract employed, producing a 0.93-fold decrease with regard to the control in the group in which *Ruta chalepensis* was administered at 100-mg/kg doses, and a 2.06-fold enzymatic induction increase in the group that was administered 30-mg/kg doses of aqueous extract. In the third group (*R. chalepensis* plus DEX, both at 100-mg/kg/day doses), there was a 5.84-fold increase in comparison with the saline solution group ([Figure 1](#F1){ref-type="fig"}; [Figure 2](#F2){ref-type="fig"}).

###### 

Fold change of messenger RNA (mRNA) as a result of intraperitoneal (i.p.) administration of aqueous extract of *Ruta chalepensis* for 3 consecutive days (n = 25)^[a](#t1f1){ref-type="table-fn"}^.

  Treatment                                                              Times of change   95% CI           *P*
  ---------------------------------------------------------------------- ----------------- ---------------- -----------------------------------------
  **Saline solution** (6.67mL/kg/day)                                    1.643 ± 1.034     0.358 ± 2.928    
                                                                                                            
  Dexamethasone (100 mg/kg/day)                                          9.949 ± 2.599     6.722 ± 13.18    *0.008[\*](#t1f2){ref-type="table-fn"}*
                                                                                                            
  *R. chalepensis* (100 mg/Kg/day)                                       0.715 ± 0.843     -0.332 ± 1.763   *0.310*
                                                                                                            
  *R. chalepensis* (30 mg/Kg/day)                                        3.702 ± 1.432     1.923 ± 5.480    *0.032[\*](#t1f2){ref-type="table-fn"}*
                                                                                                            
  ^[&](#t1f3){ref-type="table-fn"}^ Dexamethasone and *R. chalepensis*   7.486 ± 2.538     4.335 ± 10.64    *0.008[\*](#t1f2){ref-type="table-fn"}*

Results are expressed as mean ± Standard Deviation (SD).

Mann--Whitney *U* test (*p* \<0.05), with respect to the saline solution.

*R. chalepensis* plus DEX, both at 100-mg/kg/day doses.

###### 

Quantification of mRNA levels in Wistar rat liver as a result of intraperitoneal (i.p.) administration of aqueous extract of *Ruta chalepensis* for 3 consecutive days (n = 25)^[a](#t2f1){ref-type="table-fn"}^

  Treatment                                                              Media ± DE (µL/ng)
  ---------------------------------------------------------------------- --------------------
  **Saline solution** (6.67mL/kg/day)                                    29 ± 1.6\*
                                                                         
  Dexamethasone (100 mg/kg/day)                                          23 ± 2.0\*
                                                                         
  *R. chalepensis* (100 mg/Kg/day)                                       26 ± 1.0
                                                                         
  *R. chalepensis* (30 mg/Kg/day)                                        25 ± 2.1\*
                                                                         
  ^[&](#t2f2){ref-type="table-fn"}^ Dexamethasone and *R. chalepensis*   20 ± 1.2\*

Results are expressed as mean ± Standard Deviation (SD). *Post Hoc* Tukey (p\<0.05), with respect to the saline solution.

*R. chalepensis* plus DEX, both at 100-mg/kg/day doses.

![Effect of the aqueous extract of *Ruta chalepensis* on the expression of messenger RNA (mRNA) of CYP3a1 in Wistar rat (*n* = 25) after 72h of treatment. Results aree expressed as the number of times of change compared with the control group (n=5), which was administered saline solution. Interaction: *Ruta chalepensis* (100 mg/kg/day) plus Dexamethasone (DEX) (100 mg/kg/day).](AJTCAM-14-62-g001){#F1}

![Real-time PCR amplification plot.](AJTCAM-14-62-g002){#F2}

Toxicity Test on Microplate {#sec2-8}
---------------------------

There was a dose-response relationship reflected by a linear regression graph ([Figure 3](#F3){ref-type="fig"}); the median Lethal Dose (LD~50~) calculated was 109.93 µg/mL.

![Transformation of the percentage of mortality of *Artemia salina* for the aqueous extract of *Ruta chalepensis*. Each point represents the mean of three repetitions per dose. The median Lethal Dose (LD~50~) calculated was 109.93 µg/mL.](AJTCAM-14-62-g003){#F3}

Discussion {#sec1-4}
==========

The drug-plant interactions produced by cytochrome P450 (CYP450) have been widely studied; thus, these interactions could attain clinical significance. In view of the toxicity evaluation results obtained by the *Artemia salina* assay, the aqueous extract of *R. chalepensis* was found to be toxic. This result coincides with other reports indicating that methanolic and aqueous extracts of *Ruta graveolens* are toxic at LD~50~ values \<100 µg/mL (Serrano-Gallardo, 2005). The present study evinced the capacity of the aqueous extract of *R. chalepensis* in modulating the expression of mRNA of CYP450. In 2005, de Freitas et al. evaluated the effect of *R. graveolens* methanolic extract for 15 days via oral route in 1,000-mg/kg doses in mice, concluding that this plant can damage diverse organs; therefore, *R. graveolens* should not be employed as a medicinal plant. On the other hand, Lee et al. (2011) conducted a study on the use of tanshinones against cancer via chemoembolization. Thus, it is important to know the type of cytochrome modulation via injectable extract route.

This study was focused on CYP3a, one of the main enzymes in the metabolization process of currently produced drugs (Mrozikiewicz et al., 2010). Previous research has reported on the assessment of different solvents used to obtain *R. chalepensis* extract; its authors have concluded that the aqueous extract contains the greatest amount of constituents and cancels the risk of ethanol, hexane, or another type of solvents interacting with the plant's constituents, which cause an effect on the cytochromes under study (Nazish et al., 2009). This is a possible explanation to the results found by Pan et al. (2011), who concluded that the petroleum ether (PE) extract of *Orthosiphon stamineus* produces the greatest inhibitor effect on CYP2C19. At the time this experiment was published, there were no other studies on *R. chalepensis* extract in cytochromes available to compare our results; however, previous research reports on the study of other plants, such as *Andrographis paniculata* (Pekthong et al., 2009), *Orthosiphon stamineus*, *Aframomum cuspidatum* (Agbonon et al., 2010), and *Centella asiatica* (Pan et al., 2011) in cell culture. *Centella asiatica* was also studied *in vivo* by Kulthong *et al.*, (2009). the authors administered the extract orally for 90 days at doses of 1,000, 100, and 10 mg/kg/day; however, their study did not report that the extract produces a modulator effect. Some of the cytochromes studied so far include the following: 1A1 (Kulthong et al., 2009; Álvarez-González et al., 2010); 1A2 and 2B1/2B2 (Pan et al., 2011; Kulthong et al., 2009); 2C9, 2D6, and 3A4 (Ponnusankar, et al., 2011; Zhou et al., 2011). The DEX adminstered produced an increase in messenger RNA (mRNA) levels in CYP3a1; these results are in agreement with those presented by Pekthong et al. (2009), Wang & Yeung (2011), Lee et al. (2011), Cantiello et al. (2009), Ooi et al. (2011), and Kishida et al. (2008); moreover, Kishida et al (2008) demonstrated that DEX is a selective inducer of CYP3a1, and that this induction is favored in Wistar rats. One of the strengths of the present study is that all of the groups were maintained, and that the same administration route was employed (Badal et al., 2011; Kondo et al., 2011).
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